Skip to content

PTSD: all studies

Page 127 of 211: studies 1,261 to 1,270 of 2,103, newest first. Back to the PTSD overview

Research

Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report.

Cureus February 19, 2025 Paria Parhami, Sydney E Moriarty, Jay Parikh et al.

N, N-dimethyltryptamine (DMT) is a potent hallucinogenic compound with increasing recreational use despite limited safety data. While DMT use has been linked to psychosis, delusional parasitosis as a specific manifestation remains unreported. We present a novel case of a 60-year-old female veteran with chronic post-traumatic stress disorder (PTSD), a history of major depressive disorder, past...

DOI: 10.7759/cureus.79308 (opens in new tab) Full text (opens in new tab) Substance-induced psychosis Drug-induced psychosis Hallucinogen-induced psychosis Substance-related psychosis +21

Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome

Journal of Clinical Gastroenterology February 17, 2025 Erin Mauney, Franklin King, Helen Burton-Murray et al. 3 citations

Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psychedelic-assisted therapy (PAT), in which serotonergic agents like psilocybin are administered in a psychotherapeutic context, has shown promise for refractory psychiatric disorders, including major depressive disorder and post-traumatic stress...

Effect of Low-Dose Ketamine Infusion in the Intensive Care Unit on Postoperative Opioid Consumption and Traumatic Memories After Hospital Discharge: A Randomized Controlled Trial.

Anesthesia & Analgesia February 5, 2025 Nuanprae Kitisin, Nattaya Raykateeraroj, Nattachai Hemtanon et al. 11 citations

Low-dose ketamine may have an opioid-sparing effect in critically ill patients but may also predispose them to traumatic memories. We evaluated the effects of low-dose ketamine infusion in the intensive care unit (ICU) on fentanyl consumption and traumatic memories after hospital discharge. This randomized, double-blind, controlled trial was conducted at a university-based surgical ICU. 118...

DOI: 10.1213/ANE.0000000000007419 (opens in new tab) Full text (opens in new tab) Ketamine Pain management Post-operative care Opioid reduction +1

Cardiovascular effects and safety of classic psychedelics.

Nature cardiovascular research February 1, 2025 Acile Nahlawi, Leon M Ptaszek, Jeremy N Ruskin 15 citations

Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including depression, post-traumatic stress disorder (PTSD), substance use disorders and anxiety. Despite the therapeutic potential of psychedelics and their increasing use in both medical and nonmedical settings, there is a paucity of data on their...

A Scoping Review of Culturally Adapted Mindfulness-Based Interventions for Communities of Color.

Journal of Integrative and Complementary Medicine February 1, 2025 Anthony Morales, Inger Burnett-Zeigler 17 citations

Introduction: Mindfulness-based interventions (MBIs) are effective in improving mental health outcomes, including depression, anxiety, and post-traumatic stress disorder (PTSD). However, research on how MBIs have been tailored for racial and ethnic minoritized communities is limited. To address this gap, this scoping review utilizes the Ecological Validity Framework to systematically explore...

DOI: 10.1089/jicm.2023.0807 (opens in new tab) Full text (opens in new tab) Communities of color Cultural adaptation Mindfulness-based interventions Racial/ethnic minorities

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.

CPT: Pharmacometrics & Systems Pharmacology February 1, 2025 Marilyn A. Huestis, William B Smith, Cathrine Leonowens et al. 3 citations

Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA...

DOI: 10.1002/psp4.13282 (opens in new tab) Full text (opens in new tab) MDMA Therapy Psychedelic medicine PTSD Treatment Drug metabolism +1

Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.

Current Psychiatry Reports February 1, 2025 Jamarie Geller, Eric Whitney 3 citations

There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for...

The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour

International Journal of Mental Health Nursing February 1, 2025 Eva Louie, Ellen Towers, Alyssa R Morse et al. 2 citations

ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder and psilocybin for treatment‐resistant depression, but the process of translating psychedelic‐assisted therapies (PAT) into more widespread use is complex. Along with establishing the efficacy and feasibility of PATs, their acceptability amongst...

DOI: 10.1111/inm.70010 (opens in new tab) Psychedelic therapy Acceptability Mental health consumer Psychedelic‐assisted therapy +4

Preliminary results from a community-based ayahuasca-assisted mental health program among a Yaqui Indigenous population in Sonora, Mexico

Journal of Psychedelic Studies January 24, 2025 Cecile Giovannetti, Anja Loizaga-Velder, Ricardo Campoy Gomez et al. 5 citations

Abstract Background The Yaqui Intercultural Medicine Clinic was established in 2020 to provide accessible, culturally-attuned treatment for substance use and mental health disorders among an Indigenous Yaqui community in Mexico. The treatment program integrates ayahuasca ceremonies and psychotherapeutic support within a community-based outpatient treatment service. This observational pilot...

DOI: 10.1556/2054.2024.00401 (opens in new tab) Ayahuasca Indigenous Mental health Population +2

Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications

Pharmaceuticals January 19, 2025 Marco Bonaso, Letizia Biso, Benedetta Zucchini et al. 13 citations

Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due to their profound effects on consciousness, emotional processing, mood, and neural plasticity. This review explores the mechanisms underlying psychedelics’ effects, focusing on their ability to modulate brain connectivity and neural circuit activity,...